Assenagon Asset Management S.A. Trims Holdings in DaVita Inc. $DVA

Assenagon Asset Management S.A. decreased its position in shares of DaVita Inc. (NYSE:DVA) by 37.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 42,628 shares of the company’s stock after selling 25,780 shares during the period. Assenagon Asset Management S.A. owned 0.06% of DaVita worth $4,843,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Elevation Wealth Partners LLC raised its holdings in DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after acquiring an additional 165 shares during the period. Canada Pension Plan Investment Board bought a new stake in DaVita during the 2nd quarter valued at approximately $43,000. iSAM Funds UK Ltd purchased a new position in DaVita in the 3rd quarter worth approximately $46,000. Stance Capital LLC bought a new position in DaVita in the 3rd quarter worth approximately $47,000. Finally, Employees Retirement System of Texas bought a new position in DaVita in the 2nd quarter worth approximately $49,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DVA shares. Barclays lifted their price objective on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. TD Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Truist Financial set a $158.00 price objective on DaVita in a research report on Thursday, February 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, DaVita currently has an average rating of “Hold” and an average target price of $155.80.

DaVita Stock Down 1.5%

Shares of NYSE:DVA opened at $154.43 on Friday. The firm has a fifty day simple moving average of $140.32 and a two-hundred day simple moving average of $128.15. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $159.42. The stock has a market capitalization of $10.32 billion, a P/E ratio of 15.58, a PEG ratio of 0.54 and a beta of 0.94.

DaVita (NYSE:DVA) last announced its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The firm had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same period in the prior year, the company earned $2.24 EPS. The business’s revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.